MedTrace Logo

Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

NCT04942834 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2024-04-26

No results posted yet for this study

Summary

This study is to assess the effectiveness and safety of using cryoballoon ablation comparing with anti-arrhythmic drug therapy as initial treatment for naive patients with persistent atrial fibrillation.

Conditions

  • Atrial Fibrillation, Persistent
  • Arrhythmias, Cardiac

Interventions

DRUG

Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone

Class I or III antiarrhythmic drug, including sotalol

DEVICE

cryoballoon ablation

Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Li-qun Wu, MD,PhD · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2025-07-31
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04942834 on ClinicalTrials.gov